Gsk annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gsk Revenue Growth & History (GSK)
Gsk reported £32.67B in revenue for fiscal 2025, an increase of 4.11% from the previous fiscal year.
View full Gsk company overviewGsk annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £32.67B | £1.29B | +4.11% |
| 2024 | 2024-12-31 | £31.38B | £1.05B | +3.46% |
| 2023 | 2023-12-31 | £30.33B | £1.00B | +3.42% |
| 2022 | 2022-12-31 | £29.32B | £4.63B | +18.74% |
| 2021 | 2021-12-31 | £24.70B | £342.0M | +1.40% |
| 2020 | 2020-12-31 | £24.35B | −£9.40B | −27.85% |
| 2019 | 2019-12-31 | £33.75B | £2.93B | +9.52% |
| 2018 | 2018-12-31 | £30.82B | £635.0M | +2.10% |
| 2017 | 2017-12-31 | £30.19B | £2.30B | +8.24% |
| 2016 | 2016-12-31 | £27.89B | £3.97B | +16.58% |
| 2015 | 2015-12-31 | £23.92B | — | — |
Gsk quarterly revenue
Q4.17
Q4.18
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | £8.41B | £423.0M | +5.30% |
| Q1 2026 | 2026-03-31 | £7.63B | — | — |
| Q4 2025 | 2025-12-31 | £8.62B | — | — |
| Q3 2025 | 2025-09-30 | £8.55B | — | — |
| Q2 2025 | 2025-06-30 | £7.99B | — | — |
| Q4 2018 | 2019-01-01 | £72.0M | £6.0M | +9.09% |
| Q4 2017 | 2018-01-01 | £66.0M | — | — |
Gsk revenue growth trends
Over the last five reported fiscal years, revenue grew from £24.35B to £32.67B, a compound annual growth rate of 6.05%. Gsk's latest reported quarter, Q2 2026, generated £8.41B in revenue, an increase of 5.30% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Gsk source filings ↗Community posts
GSK presents Jideytro data supporting a potential first-line lung-cancer filing
GSK ($GSK) reported a 94% response rate for Jideytro in 94 evaluable patients with ROS1-positive advanced lung cancer who had not previously received a ROS1 tyrosine kinase inhibitor. In the single-arm Phase 1/2 ARROS-1 study, 90% were prog ...
